Audit: QRS - Meclizine for Health & Longevity
Audit conducted on 09/09/2026 09:17 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells vs ER lines 324/326/332, time cells vs ER 378/152/144, benefit and risk tiers vs the ER section headings, gates vs ER 280-304, monitoring table and qualitative list vs ER 406-425. No unsupported claim found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing carried over: “No human protocol exists” (action_2_sub, ER line 326), “No established target” (marker_9_target, ER line 416), “No human time course” (time_3_value, ER line 378). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening. at_a_glance keeps the ER’s associational wording (“sustained exposure is tied to later memory decline”; ER line 449) and the speculative tier keeps “in rodents” / “preclinical”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No category migration. “Vestibular rehabilitation and repositioning manoeuvres” is a caution in the ER Key Interactions & Contraindications bullet list (line 294) and appears under Key Interactions; the anticholinergic-botanical bullet is flagged “absolute contraindication” in the ER (line 292) and appears under Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, citations, expert names, NCT identifiers or brand names appear anywhere in the QRS body. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Register matches the ER: measured, evidence-weighted, explicit about where evidence stops. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven while remaining accessible; tiers and targets give the reader actionable structure without exhortation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and thresholds rather than issuing directives; no prescriptive second-person framing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advice-implying constructions; dosing text describes the labelled and extrapolated protocols as they stand in the ER rather than instructing. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommend”, “advise”, “should”, or “must” in the QRS body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns (“you”, “your”) anywhere in the QRS body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; technical terms appear only where they are the biomarker’s or drug class’s actual name (MoCA, CYP2D6, eGFR), carried verbatim from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every section is compressed to single-line tier summaries, short gate items and three-column table rows. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | The reader is never addressed directly. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content is pitched at risk-aware self-directed adults: exposure ceilings, burden scores and a longevity-curious protocol sit alongside the licensed use. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to track dosing days, run cognitive and mobility testing, and audit total anticholinergic burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for the general population; the monitoring and qualitative sections presume sustained self-measurement. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects the longevity audience: at_a_glance and action_2 both surface that the lifespan signal is rodent-only and unreplicated, the point that most distinguishes this audience’s read from the average user’s. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; framing is in longevity terms. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout. “a dummy tablet” in at_a_glance is the ER Conclusion’s own wording (line 447) and is required there by item 7.4’s plain-language rule. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verbatim: “Protocol” (line 445), “Time to effect” (491), “Benefits” (542), “Risk & Side Effects” (620), “Monitoring” (651), “Qualitative Assessment” (797), “Contraindications” (569), “Key Interactions” (587); tier labels High/Medium/Low/Speculative and column headers Marker/Target/Why unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 named template spans plus the repeatable marker_#* and qualitative_item# spans are present; set difference against the template’s span list is empty. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Line-by-line diff of the QRS body against the template shows changes confined to variable regions; all structural markup, the website=”…” spans and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relied on by the QRS is empty; every mapped ER section carries content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER’s bold labels verbatim: “Standard symptomatic protocol”, “Conservative longevity-curious protocol”, “Best time of day” (ER lines 324, 326, 332). Monitoring row labels are the ER biomarker names verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased or abbreviated where the ER supplies one. The three Time-to-Effect labels are necessarily derived, since the ER carries a single “Time to effect:” bullet, and they track the ER’s own benefit headings. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters present anywhere in the file; the ER’s “⚠️ Conflicted” markers and tier squares are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: 4 of 11 ER protocol bullets used, benefits and risks collapsed to one line per tier, gate items stripped to the key fact, and the ER monitoring table’s Context/Notes column dropped. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after “<!doctype html>” on line 1, and before any other comment or markup. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens with “—” on line 3 and closes with “—” on line 13; the preceding title text on line 2 sits outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is inside an HTML comment and is not echoed by any element on the sheet. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and unquoted except duration: “00:03”, which contains a colon and therefore requires YAML quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: meclizine_2026-0909-0710_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0909-0914, in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: meclizine_2026-0909-0710_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Frontmatter values are clean and consistent; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Meclizine for Health & Longevity - Quick Reference Sheet”, the ER canonical_topic with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Meclizine for Health & Longevity”, matching the ER canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/09/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0909-0914. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only title and the template’s standard subline; no badge, version stamp, alternate-names line, source-AI attribution, audit date or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 447-451) into benefit window, benefit ceiling, harm profile and longevity status. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, within the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: acute relief and travel sickness (line 447), benefit evaporating and daily use no better than placebo (447), drowsiness, falls and memory decline (449), rodent basis (451). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or technical classifications; plain-language substitutes are used throughout (“sudden dizzy spell”, “travel sickness”, “a dummy tablet”, “slowed thinking”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, risk ratios or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section (ER lines 278-304). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER contraindications are represented: the seven “Populations who should avoid Meclizine” bullets (ER 298-304) plus the anticholinergic-botanical combination flagged as an absolute contraindication (ER 292). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is a discrete <li></li> inside the [stop_items] span (lines 572-582). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing ER explanations stripped, e.g. “Adults with myasthenia gravis, a disorder of nerve-to-muscle signalling that anticholinergics worsen” reduced to “Myasthenia gravis”; the botanical bullet’s mechanism clause removed. No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers preserved: “(post-void residual above 150 mL)”, “(Child-Pugh Class C)”, “(first 24 hours)”, “below 26”, “Aged 75 or older … preceding 12 months”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, which is correct: the ER identifies eight populations or combinations to avoid. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section (ER lines 280-294). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven ER caution bullets are present and the anticholinergic-botanical bullet is correctly excluded, since it is already carried as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is a discrete <li></li> inside the [caution_items] span (lines 590-610). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mechanism and mitigation clause after the colon is stripped; only the interacting class and its example list remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All ER example drug lists preserved verbatim, e.g. “(alcohol, opioids, benzodiazepines, zolpidem, gabapentinoids)” and “(fluoxetine, paroxetine, bupropion, quinidine)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, which is correct: the ER identifies eight interactions that change how the intervention is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER lines 322-344). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three most actionable aspects are selected from the ER’s eleven bullets: the standard symptomatic protocol, the conservative longevity-curious protocol, and best time of day. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names eleven distinct actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; labels and values are drawn from ER lines 324, 326 and 332. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Three aspects covered: acute vertigo relief (ER 378, 144), motion-sickness prevention (ER 152) and the absence of a human time course for the metabolic and lifespan claims (ER 378). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order tracks benefit magnitude: acute vertigo relief is the ER’s only High benefit, motion-sickness prevention is Medium, and the lifespan claim is Speculative. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry meaningful ER-derived content; time_1_sub and time_3_sub are near-verbatim from ER line 378. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (ER line 378), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER lines 136-192). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans are present and populated (lines 544-562). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER benefit heading alone; no magnitudes, confidence intervals, trial descriptions or mechanisms carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the ER’s “⚠️ Conflicted” markers are also dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers contain items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER lines 208-262). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans are present and populated (lines 622-645). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER risk heading alone; hazard ratios, risk ratios and mechanistic detail are all excluded. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content, frequencies or severity grades survive. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers contain items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER lines 402-416). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarker table rows are carried across in ER order, with names, targets and rationales matching ER lines 408-416. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated verbatim from the ER’s cadence sentences (ER line 404): event-driven reassessment after the first dose, at 4 weeks, then every 6-12 months, with annual repeats above 30 dosing days a year. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER lines 418-425). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are listed verbatim and in ER order. |
Issues 09/09/2026 09:17
Pass rate 100.00%. No issues found.